Overview

Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer

Status:
Completed
Trial end date:
2018-10-19
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the efficacy of rovalpituzumab tesirine as a third-line and later treatment for participants with relapsed or refractory delta-like protein 3 (DLL3) expressing small cell lung cancer (SCLC).
Phase:
Phase 2
Details
Lead Sponsor:
AbbVie
Stemcentrx